Meeting
2015 Genitourinary Cancers Symposium
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy.
Authors
Orvar Gunnarsson
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Wei-Ting Hwang , Christian Michael Squillante , Katherine L. Nathanson , Edward A. Stadtmauer , David J. Vaughn , Orvar Gunnarsson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 398)
DOI
10.1200/jco.2015.33.7_suppl.398
Abstract #
398
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.
First Author: Adam Uprichard
Poster
2019 ASCO Annual Meeting
Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).
First Author: Darren R. Feldman
Poster
2015 Genitourinary Cancers Symposium
Prognostic factor for overall survival in the "difficult-to-treat" germ cell tumor patients.
First Author: Terukazu Nakamura
Poster
2014 ASCO Annual Meeting
Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine, paclitaxel, ifosfamide, and cisplatin (Gem-TIP).
First Author: Matthew James Wheater